Please login to the form below

Not currently logged in
Email:
Password:

CSL

This page shows the latest CSL news and features for those working in and with pharma, biotech and healthcare.

Shire’s angioedema drug Takhzyro claims EU approval

Shire’s angioedema drug Takhzyro claims EU approval

The switchovers includes some patients on Cinryze but also competitors’ products, he said.  At the moment Shire’s big competitor in HAE is CSL with its Haegarda product, a subcutaneous medicine

Latest news

More from news
Approximately 3 fully matching, plus 42 partially matching documents found.

Latest Intelligence

  • Pharma deals continue to slide Pharma deals continue to slide

    425 (upfront 80). Calimmune (US). CSL (AU). Company acquisition. Preclinical haematopoietic stem cell therapy for sickle cell disease.

  • Deal Watch January 2017 Deal Watch January 2017

    625. Momenta. CSL. Licence. M230 immuno-modulator of Fc receptors. 600. ImmuNext.

  • Pharma deals in June 2015 Pharma deals in June 2015

    85. BioCryst Pharmaceuticals/ CSL. RAPIVAB (peramivir injection) for the treatment of influenza (marketed).

  • Deal Watch table for October 2014 Deal Watch table for October 2014

    318. Novartis/CSL. Asset purchase. Influenza vaccines. 275. Five Prime/GSK. Expansion of collaboration.

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    Parenterally administered DTIs. Four parenterally administered DTIs are currently available on the market: lepirudin (Refludan; CSL Behring), desirudin (Revasc; Novartis), bivalirudin (Angiox; Biogen Idec) and argatroban (Novastan; Mitsubishi

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

  • Bartenbach adds to healthcare management team Bartenbach adds to healthcare management team

    Anja Treiber has worked with CSL Behring, Novo Nordisk, Fresenius Kabi and Merz Pharma. ... In the last two years, Treiber has focused on international pharma clients including CSL Behring, Novo Nordisk, Fresenius Kabi and Merz Pharma.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Resolute

Publicis Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team with a...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics